Results 191 to 200 of about 20,867 (266)

Cardiometabolic Profiles of Oral and Subcutaneous Glucagon‐Like Peptide‐1 Receptor Mono‐Agonists in Adults With Overweight or Obesity: A Systematic Review and Network Meta‐Analysis

Diabetes, Obesity and Metabolism, Volume 28, Issue 7, Page 5761-5766, July 2026.
ABSTRACT Aims To characterize the cardiometabolic profiles of oral and subcutaneous glucagon‐like peptide‐1 (GLP‐1) receptor mono‐agonists in adults with overweight or obesity, with or without type 2 diabetes (T2D), using network meta‐analysis (NMA).
Ying Lu, Jiajie Chen, Yuqing Guo, Hao Ding, Yu‐Lun Liu, Michelle A. Van Name, Mona Sharifi, Yuan Lu, Yong Chen   +8 more
wiley   +1 more source

Real-world effectiveness and safety of tirzepatide in Japanese patients with type 2 diabetes: A multi-site retrospective study. [PDF]

Diabetes Obes Metab
Minakata Y, Miura M, Nakatake N, Masuzawa M.   +3 more
europepmc   +1 more source

Use of Glucagon‐Like Peptide‐1 Receptor Agonists and Risk of Parkinson's Disease: Scandinavian Cohort Study

Diabetes, Obesity and Metabolism, Volume 28, Issue 7, Page 5767-5778, July 2026.
ABSTRACT Aims To investigate the association between use of GLP‐1 receptor agonists and incident Parkinson's disease. Material and Methods Cohort study using data from nationwide registers in Denmark, Norway and Sweden and an active‐comparator, new‐user design.
Arvid Engström, Henrik Svanström, Anders Hviid, Björn Eliasson, Soffia Gudbjörnsdottir, Viktor Wintzell, Kristian Hveem, Christian Jonasson, Mads Melbye, Peter Ueda, Björn Pasternak   +10 more
wiley   +1 more source

Emerging Role of Dual Glucagon-Like Peptide-1 (GLP-1)/Glucose-Dependent Insulinotropic Polypeptide (GIP) Receptor Agonists in Cardiovascular Prevention. [PDF]

Cureus
Contreras Figueroa N, Lopez Mendoza MJ, Ulloa A, Jiron Vindas J, Salazar Estrada MA, Valle Mena MJ.   +5 more
europepmc   +1 more source

Indirect Comparative Efficacy and Safety of Tirzepatide Versus Oral Semaglutide for the Treatment of Overweight and Obesity

Diabetes, Obesity and Metabolism, Volume 28, Issue 7, Page 6162-6171, July 2026.
ABSTRACT Aims Tirzepatide, an injectable glucose‐dependent insulinotropic polypeptide (GIP) and glucagon‐like peptide‐1 (GLP‐1) receptor agonist (RA), is approved for weight management in several regions. Oral GLP‐1 RAs, such as semaglutide, are under investigation to improve convenience, acceptance and adherence versus injectable formulations ...
Andreea Ciudin, Erin Johansson, Sarah Zimner‐Rapuch, Georgios K. Dimitriadis, Mathias Hempfling, Laura J. Clark, Ludi Fan, Helene Sapin   +7 more
wiley   +1 more source

Comparative pharmacovigilance analysis of suicidality-related adverse events among GLP-1 and non-GLP-1 anti-obesity drugs in the FDA Adverse Event Reporting System. [PDF]

Int J Clin Pharm
Seijas-Amigo J, Salgado-Barreira Á, Rodriguez-Penas D, Cardeso-Paredes B, Ribeiro-Ferreiro M, Rodriguez-Mañero M, Gonzalez-Juanatey JR.   +6 more
europepmc   +1 more source

Sitagliptin, Metformin and Glimepiride Fixed‐Dose Combination Compared to Co‐Administration of Metformin and High‐Dose Glimepiride in Indian Patients With Type 2 Diabetes: A Randomised, Double‐Blind, Double‐Dummy, Phase 3 Clinical Study

Diabetes, Obesity and Metabolism, Volume 28, Issue 7, Page 6207-6216, July 2026.
ABSTRACT Aims This study assessed the efficacy and safety of a triple fixed‐dose combination (FDC) of sitagliptin, metformin, and glimepiride versus co‐administered metformin and glimepiride in Indian patients with uncontrolled Type 2 diabetes (T2D).
Rakesh Sahay, Ambanna Gowda, Manish Kumar Singh, A. Gopal Rao, Ramesh Duraisamy, Dinesh Gangwani, Jitendra Shukla, Vikas Agarwal, Sandesh Sahebarao Patil, Ambrish C., Satish Babu K. N., Arvind Palawat, Sandip Krishnrao Gofne, Abhay Kumar Sahoo, Pradeep Kumar Rai, Raisa Shaikh, Shruti Saha, Dipak Patil, Pravin Ghadge, Piyush Patel, Lalit Lakhwani, Suyog Mehta, Sadhna Joglekar   +22 more
wiley   +1 more source

Reconsidering Obesity in India Through a Gut-Metabolic Lens: Mechanistic Insights and the Emerging Role of Synbiotics in Individuals with the Thin-Fat Phenotype. [PDF]

Adv Ther
Ganguly NK, Kalra S, Kapoor N, Rao P, Bakshi M.   +4 more
europepmc   +1 more source

Higher Body Mass Index Is a Causal Risk Factor for Skin Infections: A Mendelian Randomisation Study Using UK Biobank and FinnGen

Diabetes, Obesity and Metabolism, Volume 28, Issue 7, Page 5907-5914, July 2026.
ABSTRACT Aims Infections remain a leading cause of mortality and morbidity globally. We aimed to evaluate the potential causal role of higher BMI on common bacterial, viral and fungal infections using Mendelian randomisation (MR). Material and Methods In UK Biobank (N = 502 131, N = 230 542 with linked GP records), we tested observational associations ...
Rhian Hopkins, Ethan de Villiers, Michael N. Weedon, Beverley M. Shields, John M. Dennis, Andrew P. McGovern, Harry D. Green   +6 more
wiley   +1 more source

Editorial: Incretin-based therapies in the treatment of metabolic syndrome: expanding roles beyond weight management

Frontiers in Endocrinology
Kexin Zhang, Kexin Zhang, Xiaodong Sun, Xiaodong Sun, Lixin Li   +4 more
doaj   +1 more source